{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:09:59Z","timestamp":1783721399408,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-91792-5","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T10:53:10Z","timestamp":1740739990000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Establishment of an \u03b1-thalassemia mouse model through fetal liver cell transplantation and analysis of hematological parameters"],"prefix":"10.1038","volume":"15","author":[{"given":"Xin","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencheng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenrui","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"91792_CR1","first-page":"339","volume":"80","author":"HL Muncie","year":"2009","unstructured":"Muncie, H. L. et al. Alpha and beta thalassemia. Am. Fam. Physician 80, 339\u2013344 (2009).","journal-title":"Am. Fam. Physician"},{"key":"91792_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101165","volume":"64","author":"KM Musallam","year":"2024","unstructured":"Musallam, K. M. et al. \u0391lpha-thalassemia: A practical overview. Blood Rev. 64, 101165 (2024).","journal-title":"Blood Rev."},{"key":"91792_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/727905","volume":"2013","author":"M Angastiniotis","year":"2013","unstructured":"Angastiniotis, M. et al. The impact of migrations on the health services for rare diseases in Europe: The example of haemoglobin disorders. Sci. World J. 2013, 727905 (2013).","journal-title":"Sci. World J."},{"key":"91792_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.hoc.2017.11.008","volume":"32","author":"DJ Weatherall","year":"2018","unstructured":"Weatherall, D. J. The evolving spectrum of the epidemiology of thalassemia. Hematol. Oncol. Clin. N. Am. 32, 165\u2013175 (2018).","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"91792_CR5","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1182\/blood-2016-08-697110","volume":"129","author":"D Songdej","year":"2017","unstructured":"Songdej, D. et al. An international registry of survivors with Hb Bart\u2019s hydrops fetalis syndrome. Blood 129, 1251\u20131259 (2017).","journal-title":"Blood"},{"key":"91792_CR6","volume-title":"Hydrops Fetalis","author":"R Vanaparthy","year":"2022","unstructured":"Vanaparthy, R. et al. Hydrops Fetalis (StatPearls Publishing, 2022)."},{"key":"91792_CR7","first-page":"107","volume":"24","author":"WY Chan","year":"2018","unstructured":"Chan, W. Y. et al. Outcomes and morbidities of patients who survive haemoglobin Bart\u2019s hydrops fetalis syndrome: 20-year retrospective review. Hong Kong Med. J. 24, 107\u2013118 (2018).","journal-title":"Hong Kong Med. J."},{"key":"91792_CR8","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.jpeds.2008.11.031","volume":"154","author":"JS Yi","year":"2009","unstructured":"Yi, J. S. et al. Homozygous alpha-thalassemia treated with intrauterine transfusions and unrelated donor hematopoietic cell transplantation. J. Pediatr. 154, 766\u2013768 (2009).","journal-title":"J. Pediatr."},{"key":"91792_CR9","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1440-1754.2007.01131.x","volume":"43","author":"SY Lee","year":"2007","unstructured":"Lee, S. Y. et al. Outcome of intensive care of homozygous alpha-thalassaemia without prior intra-uterine therapy. J. Paediatr. Child Health 43, 546\u2013550 (2007).","journal-title":"J. Paediatr. Child Health"},{"key":"91792_CR10","doi-asserted-by":"publisher","first-page":"5035","DOI":"10.1074\/jbc.M211110200","volume":"278","author":"T Shirasawa","year":"2003","unstructured":"Shirasawa, T. et al. Oxygen affinity of hemoglobin regulates O2 consumption, metabolism, and physical activity. J. Biol. Chem. 278, 5035\u20135043 (2003).","journal-title":"J. Biol. Chem."},{"key":"91792_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/ajh.2830420117","volume":"42","author":"KM McKie","year":"1993","unstructured":"McKie, K. M. et al. Postnatal changes in the quantities of globin chains and hemoglobin types in two babies with Hb H disease. Am. J. Hematol. 42, 86\u201390 (1993).","journal-title":"Am. J. Hematol."},{"key":"91792_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/ng0995-33","volume":"11","author":"C P\u00e1szty","year":"1995","unstructured":"P\u00e1szty, C. et al. Lethal alpha-thalassaemia created by gene targeting in mice and its genetic rescue. Nat. Genet. 11, 33\u201339 (1995).","journal-title":"Nat. Genet."},{"key":"91792_CR13","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/(SICI)1097-0223(199808)18:8<838::AID-PD341>3.0.CO;2-#","volume":"18","author":"TY Fung","year":"1998","unstructured":"Fung, T. Y. et al. In utero exchange transfusion in homozygous alpha-thalassaemia: A case report. Prenat. Diagn. 18, 838\u2013841 (1998).","journal-title":"Prenat. Diagn."},{"key":"91792_CR14","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1007\/s11136-014-0671-2","volume":"23","author":"FL Trachtenberg","year":"2014","unstructured":"Trachtenberg, F. L. et al. Relationship among chelator adherence, change in chelators, and quality of life in thalassemia. Qual. Life Res. 23, 2277\u20132288 (2014).","journal-title":"Qual. Life Res."},{"key":"91792_CR15","volume-title":"2021 Guidelines: For the Management of Transfusion Dependent Thalassaemia (TDT)","author":"MD Cappellini","year":"2023","unstructured":"Cappellini, M. D. et al. 2021 Guidelines: For the Management of Transfusion Dependent Thalassaemia (TDT) 4th edn. (Thalassaemia International Federation, 2023).","edition":"4"},{"key":"91792_CR16","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1111\/trf.14875","volume":"58","author":"A Lal","year":"2018","unstructured":"Lal, A. et al. Transfusion practices and complications in thalassemia. Transfusion 58, 2826\u20132835 (2018).","journal-title":"Transfusion"},{"key":"91792_CR17","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.hoc.2022.12.009","volume":"37","author":"M Algeri","year":"2023","unstructured":"Algeri, M. et al. Hematopoietic stem cell transplantation in thalassemia. Hematol. Oncol. Clin. N. Am. 37, 413\u2013432 (2023).","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"91792_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/03630260701297204","volume":"31","author":"G Bozkurt","year":"2007","unstructured":"Bozkurt, G. Results from the north cyprus thalassemia prevention program. Hemoglobin 31, 257\u2013264 (2007).","journal-title":"Hemoglobin"},{"key":"91792_CR19","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1097\/01.HS9.0000848940.29840.9b","volume":"6","author":"S Rivella","year":"2022","unstructured":"Rivella, S. et al. P1521: A Sever mouse model of alpha-thalassemia shows abnormal iron metabolism, erythropoiesis and coagulation, and can be rescued by a novel gene therapy approach. HemaSphere 6, 1402\u20131403 (2022).","journal-title":"HemaSphere"},{"key":"91792_CR20","volume":"6","author":"B Ali","year":"2018","unstructured":"Ali, B. et al. The role of immune system in thalassemia major: A narrative review. J. Pediatr. Rev. 6, e14508 (2018).","journal-title":"J. Pediatr. Rev."},{"key":"91792_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00277-008-0564-y","volume":"88","author":"M Gharagozloo","year":"2009","unstructured":"Gharagozloo, M. et al. Double-faced cell-mediated immunity in beta-thalassemia major: Stimulated phenotype versus suppressed activity. Ann. Hematol. 88, 21\u201327 (2009).","journal-title":"Ann. Hematol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91792-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91792-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91792-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T10:53:13Z","timestamp":1740739993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91792-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91792"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91792-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"8 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were conducted in accordance with the ARRIVE Guidelines, the Guide for the Care and Use of Laboratory Animals (), and the Institutional Animal Care and Use Committee (IACUC) of Gempharmatech Co., Ltd., following approval by the Animal Ethics Committee (GPTAP20231109-6). To thoroughly consider the ethical implications of using fetal liver cells for transplantation, we evaluated several alternative methods before selecting fetal liver cells as the experimental material. While adult stem cells and other cell types can be used in some studies, fetal liver cells offer unique advantages in mimicking the pathophysiology of human \u03b1-thalassemia. Fetal liver cells contain a high number of hematopoietic stem cells, which more accurately reflect the disease state. The aim of this study is to develop a new mouse model to better understand the pathogenic mechanisms of \u03b1-thalassemia and provide a platform for future therapeutic strategies. This model will enable us to investigate the molecular mechanisms of the disease and test potential treatments, particularly gene therapy. We believe that the potential scientific and societal benefits of this research outweigh the ethical risks.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"7183"}}